Also, whether both copies of BRCA2 are inactivated in cancers from mutation carriers is proving to be quite important because sensitivity to targeted therapies, like platinum compounds or poly-ADP ribose polymerase (PARP) inhibitors, only occurs when that second wild-type copy of BRCA2 is lost. The gene discussed is BRCA2; the disease is cancer.